Drug profile · INN
sebelipase alfa
KANUMA
sebelipase alfa (KANUMA) is a cholesterol ester hydrolytic enzyme. Route of administration: injection. Current US regulatory status: approved.
Drug details — sebelipase alfa
- US status
- approved
- Class
- Alimentary tract and metabolism (A16)
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
sebelipase alfa (KANUMA) is a cholesterol ester hydrolytic enzyme. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Cholesterol ester hydrolytic enzyme
Primary target: Cholesterol ester
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| PMDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is sebelipase alfa?
sebelipase alfa (KANUMA) is a cholesterol ester hydrolytic enzyme. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for sebelipase alfa?
KANUMA is a marketed brand name for sebelipase alfa. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of sebelipase alfa?
sebelipase alfa has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.